By cultivating new approaches to gathering data on the effects of cardiovascular disease in different patient groups, our researchers are innovating pipelines that accelerate the discovery, translation and implementation potential of lead compounds.
Through cross-disciplinary collaboration with the Cardiovascular Initiative and the Charles Perkins Centre, we are leading efforts in revolutionising how we think about and research cardiovascular drugs.
Cardiovascular diseases are estimated to contribute to over 16 million deaths each year. Driven by a raft of behavioural, environmental, and genetic factors, there are numerous disorders of the heart, arteries and blood vessels that disrupt critical bodily functions.
Atherosclerosis is a leading cardiovascular disease caused and accelerated by a buildup of plaque in arteries and blood vessels.
Co-led by Prof Arnold Lining Ju and A/Prof Mary Kavurma, the Peripheral and Carotid Artery Disease Initiative seeks to address knowledge gaps in atherosclerosis research.
Our team of researchers based across the University of Sydney and the Heart Research Institute is elevating approaches to coronary, carotid and peripheral artery disease pathogenesis. We’re developing thrombosis and atherosclerosis on-a-chip models, identifying new biomarkers and diagnostic tools to invent more effective targeted therapies.
I started studying Peripheral Artery Disease because it's one of the most under-recognised, underdiagnosed, and understudied forms of cardiovascular disease. It deserves far more attention than it currently receives.
PCADI Co-leader, Leader of Vascular Complications Group at the Heart Research Institute
Developing precision covalent therapeutics to target protein disulfide isomerase A6.
We are uncovering new compounds to accelerate the development of therapeutic inhibitors for treating acute ischemic stroke.
We are developing chemical inhibitors of a novel oxygen sensing system implicated in angiogenesis, the process of forming new blood vessels, to establish new drugs for the treatment of ischemic heart disease.
The accumulation of senescent endothelial cells contribute to age-related-pathologies such as cardiovascular disease. Here, we are developing small molecule inhibitors to block this process.
Creating mature cardiomyocytes from patient-derived induced pluripotent stem cells to assess anti-arrhythmic drugs.
Researchers have combined plasma activated coating technology with arrhythmia patient-derived induced pluripotent stem cell derived cardiomyocytes to create an in vitro model of arrythmia.
Unlocking cardiovascular disease by engineering patient-specific blood vessel mimics.
This project is establishing the first ever patient-specific blood vessel mimic in vitro by leveraging the power of a novel perfusion bioreactor and a first of its kind biobank of patient-derived cells collected from a nation-wide cohort study.
